CSL Behring Awards Global Grants to Next Generation of Coagulation Researchers

    Prof. Heimburger Awards Presented at Formal Ceremony During Hemophilia
    World Congress

    ISTANBUL, Turkey, June 3 /CNW/ -- CSL Behring, a global leader in the
protein biotherapeutics industry, today awarded CSL Behring - Prof. Heimburger
Award grants to five young medical researchers at the Hemophilia 2008 World
Congress of the World Federation of Hemophilia (WFH). The start-up grants of
20,000 euros (approximately $27,000 US) each were awarded to the recipients
for preclinical and/or clinical research in the area of coagulation. Projects
were selected based on the scientific merit of the work.
    The grant is named in honor of Professor Dr. Norbert Heimburger, a
pioneer of modern coagulation therapy and a CSL Behring employee for more than
three decades. Among his many achievements was the development of virus-safe
plasma products based on pasteurization. Due to his research efforts, the
company launched the world's first effectively virus-inactivated FVIII
concentrate in 1981. Prof. Dr. Heimburger, honored with the Order of Merit of
the Federal Republic of Germany in 1981, passed away in September 2006.

    The 2008 award recipients are as follows:
     -- Sebastien Andre, Immunopathologie et immunointervention therapeutique,
        Centre de Recherche des Cordeliers (CRC), Paris, France

     -- Yesim Dargaud, Hopital Edouard Herriot Laboratoire d'Hemostase Unite
        d'Hemostase Clinique Pav.E., Lyon, France

    -- Paula James, Queen's University, Kingston, Ontario, Canada

     -- Carolyn Miller, Katharine Dormandy Haemophilia Centre & Haemostasis
        Unit Royal Free & University College Medical School, London, UK

     -- Jorg Schuttrumpf, Institut fur Transfusionsmedizin und
        Immunhamatologie DRK-Blutspendedienst Baden-Wurttemberg-Hessen, Johann
        Wolfgang Goethe Universitat, Frankfurt, Germany
    "CSL Behring is proud to support the excellent efforts of these
clinicians as part of our commitment to advancing the science and
understanding of coagulation," said Val Romberg, Head of Research and
Development at CSL Behring. "Allowing the next generation of coagulation
researchers to establish themselves in this therapeutic area is critical to
improving treatment and outcomes for patients with bleeding disorders."
    Applications were reviewed by a special selection committee of four
renowned clinicians in the coagulation field: Erik Berntorp, MD, PhD, Malmo
University Hospital, Sweden; Jorge DiPaola, MD, Great Plains Regional
Hemophilia Treatment Center, USA; David Lillicrap, MD, FRCPC, Queen's
University, Canada; and Johannes Oldenburg, MD. PhD, University of Bonn,
    For more information regarding the Prof. Heimburger Award and specific
criteria for 2009 applications, please go to
    About CSL Behring
    CSL Behring is a global leader in the protein biotherapeutics industry.
Passionate about saving and improving the quality of patients' lives, CSL
Behring manufactures and markets a range of safe and effective plasma-derived
and recombinant products and related services. The company's therapies are
used in the treatment of rare diseases such as immune deficiency disorders,
hemophilia, von Willebrand disease, other bleeding disorders and inherited
emphysema. Other products are used for the prevention of hemolytic diseases in
the newborn, in cardiac surgery, organ transplantation and in the treatment of
burns. The company also operates one of the world's largest plasma collection
networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a
biopharmaceutical company with headquarters in Melbourne, Australia. For more
information, visit www.cslbehring.com.

    Sheila A. Burke, Director, Communications & Public Relations
    Worldwide Commercial Operations
    CSL Behring

For further information:

For further information: Sheila A. Burke, Director, Communications & 
Public Relations, Worldwide Commercial Operations of CSL Behring, 
+1-610-878-4209, Sheila.Burke@cslbehring.com Web Site:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890